Back

GLP1 agonist: for everyone?

31 August 2026 (09:09 - 09:27)
Organised by: Logo
Congress Presentation Part of: Assessing and treating 'residual risk' beyond low-density lipoproteins Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Erin Michos

The Johns Hopkins University School of Medicine, Baltimore (United States of America)

4 More presentations in this session

Presentation thumbnail
Optimal ways to identify high-risk cohorts beyond low-density lipoproteins: unmet high-risk patients
Doctor P. Ridker (Boston, US)
Slides Video
Presentation thumbnail
Targeting lipoprotein(a)
Professor B. Nordestgaard (Copenhagen, DK)
Slides Video
Presentation thumbnail
Colchicine: who benefits?
Doctor J. Tardif (Montreal, CA)
Slides Video
Presentation thumbnail
Assessing and treating 'residual risk' beyond low-density lipoproteins - discussion
Video

Access the full session

Session thumbnail
Assessing and treating 'residual risk' beyond low-density lipoproteins
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 09:09 CET
You may be interested in
thumbnail
Congress Session
A multidisciplinary approach to type 2 diabetes, obesity, and cardiovascular diseases: current evidence and a glimpse into the future
27 August 2023
thumbnail
Congress Presentation
Should GLP-1 receptor agonists be used for population-level prevention?: pro
30 August 2026
thumbnail
Congress Presentation
Are GLP-1 agonists panacea for cardiovascular disease
30 August 2026
thumbnail
Congress Presentation
GLP-1 agonists: drug for weight loss - are they longevity agents?
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources